STOCK TITAN

Kiora Pharmaceuticals, Inc. - KPRX STOCK NEWS

Welcome to our dedicated page for Kiora Pharmaceuticals news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on Kiora Pharmaceuticals stock.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company committed to the development and commercialization of innovative treatments for orphan retinal diseases. The company's lead product candidate, KIO-301, is aimed at treating inherited retinal diseases such as retinitis pigmentosa, choroideremia, and Stargardt disease. KIO-301 is a molecular photoswitch with the potential to restore vision in patients suffering from inherited and age-related retinal degeneration.

Kiora’s second key asset, KIO-104, is being developed to treat posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, with the promise of reducing retinal inflammation without the adverse effects associated with systemic anti-inflammatory drugs or chronic steroid use.

Most recently, Kiora announced its third quarter 2023 financial results and discussed the advancement of KIO-301 for other inherited retinal diseases. The ABACUS-1 study, a Phase 1b clinical trial of KIO-301, demonstrated safety and tolerability, along with significant improvements in visual field and functional vision. These promising results have paved the way for the company to initiate the ABACUS-2 trial, a Phase 2 study involving up to 20 patients with retinitis pigmentosa.

The company also entered into a strategic development and commercialization agreement with Théa Open Innovation (TOI), providing up to $285 million in potential milestone payments, alongside reimbursement of research and development expenses. This partnership will help Kiora accelerate the development and commercialization of KIO-301 globally, excluding Asia.

Moreover, Kiora announced a successful securities purchase agreement, raising up to $45 million to support its ongoing development activities. Recent strategic partnerships and financial maneuvers are expected to fund the company’s operations through 2026, offering a robust financial foundation for future growth.

Operating from Encinitas, California, Kiora continues to pioneer in the biotech space, aiming to bring transformative therapies to market for patients suffering from rare retinal diseases. The company remains focused on delivering innovative solutions that address significant unmet medical needs in ophthalmology.

Rhea-AI Summary
Kiora Pharmaceuticals, Inc. announces its 2023 financial results and plans for 2024, focusing on the development of KIO-301 and KIO-104 for retinal diseases. The company's strategic partnership with Théa Open Innovation and private placement are expected to fund operations through 2026. Kiora aims to advance innovative drug candidates for rare retinal diseases, with KIO-301 potentially becoming the first vision-restoring option for patients with RP. The company also highlights achievements, upcoming milestones, and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
-
Rhea-AI Summary
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced positive results from a Phase 1 study of KIO-101, a non-steroidal anti-inflammatory agent, showing significant reduction in conjunctival hyperemia in the eye. KIO-101 is well tolerated and aims to reduce T-cell-related inflammation locally in the eye without systemic side effects. The company plans a Phase 2 trial for KIO-104 to target posterior non-infectious uveitis, a rare inflammatory condition of the retina.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
-
Rhea-AI Summary
Kiora Pharmaceuticals, Inc. has announced a securities purchase agreement with healthcare investors to raise up to $45 million in gross proceeds, including $15 million in upfront funding and up to an additional $30 million upon exercise of accompanying warrants. The financing includes participation from new healthcare-dedicated investors, and the company will issue an aggregate of 27,154,237 shares of its common stock and accompanying warrants. The financing will provide flexibility to fully fund KIO-104 for the treatment of non-infectious uveitis and potentially other rare inflammatory indications in the back of the eye.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
53.99%
Tags
none
Rhea-AI Summary
Kiora Pharmaceuticals, Inc. has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI) for the treatment of degenerative retinal diseases, excluding Asia. Kiora will receive an upfront payment of $16 million and up to $285 million upon achieving milestones, along with royalties of up to low 20% on net sales. The agreement is based on the Phase I/II data of KIO-301 in Retinitis Pigmentosa, which showed significant vision improvements in patients. KIO-301 is a small molecule designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs) in patients with inherited retinal disease. The company will host an investor call to discuss the partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
53.99%
Tags
-
Rhea-AI Summary
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its Q3 2023 financial results and plans to advance clinical development of KIO-301 for inherited retinal diseases. ABACUS-1 study showed KIO-301 is safe and tolerable, with significant improvements in visual field and brain activity. Kiora will expand clinical development of KIO-301 for multiple inherited retinal diseases, including RP, CHM, and Stargardt disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
-
Rhea-AI Summary
Kiora Pharmaceuticals announces positive Phase I/II results for KIO-301, a small molecule for improving vision in patients with Retinitis Pigmentosa. The study showed significant improvement in visual field and functional vision, as well as increased brain activity in the visual cortex. The molecule is safe and well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Kiora Pharmaceuticals invites investors to view online presentation at Lytham Partners Fall 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
conferences
-
Rhea-AI Summary
Kiora Pharmaceuticals receives approval to enroll additional patients in ABACUS study of KIO-301 for Retinitis Pigmentosa and Choroideremia, plans to report results on November 4th. Preliminary data shows KIO-301 safe and tolerable with signs of efficacy. Kiora's 'gene mutation-agnostic approach' has potential to make an impact in both diseases. Partnership with Choroideremia Research Foundation aids in trial enrollment and future study designs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
-
Rhea-AI Summary
Kiora Pharmaceuticals appoints Praveen Tyle as new Chairman, succeeding Paul Chaney. Tyle's leadership and industry experience expected to guide development of new treatments for eye disease. Tyle will continue to guide strategic direction as the Company advances development of KIO-301 for retinal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
management
Rhea-AI Summary
Kiora Pharmaceuticals completes patient evaluation for vision restoration drug in clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags

FAQ

What does Kiora Pharmaceuticals specialize in?

Kiora Pharmaceuticals specializes in developing and commercializing treatments for orphan retinal diseases such as retinitis pigmentosa, choroideremia, and Stargardt disease.

What are Kiora's key product candidates?

Kiora’s key product candidates are KIO-301, a molecular photoswitch for inherited retinal diseases, and KIO-104, an immuno-modulatory inhibitor for treating posterior non-infectious uveitis.

What recent clinical trial results has Kiora announced?

Kiora announced positive results from the ABACUS-1 study, demonstrating that KIO-301 is safe and tolerable, with significant improvements in visual field and functional vision.

What partnerships has Kiora Pharmaceuticals formed recently?

Kiora has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI), providing significant financial support and global development expertise.

How is Kiora Pharmaceuticals funded for its operations?

Kiora is funded through strategic partnerships, such as the one with TOI, and successful securities purchase agreements, providing a robust financial foundation expected to last through 2026.

What is the focus of Kiora’s KIO-104 product candidate?

KIO-104 focuses on treating posterior non-infectious uveitis and aims to reduce retinal inflammation without the side effects of systemic anti-inflammatory drugs or chronic steroids.

What are the latest financial results for Kiora Pharmaceuticals?

In the third quarter of 2023, Kiora reported net losses and increased R&D expenses due to clinical trials, with a strategic focus on advancing KIO-301 and KIO-104.

Where is Kiora Pharmaceuticals headquartered?

Kiora Pharmaceuticals is headquartered in Encinitas, California.

What is retinitis pigmentosa?

Retinitis pigmentosa is a hereditary degenerative disorder affecting the retina's photoreceptors, leading to progressive vision loss. There are currently no approved therapies.

How can investors stay updated on Kiora Pharmaceuticals?

Investors can stay updated by following Kiora’s news releases, SEC filings, and social media accounts or by subscribing to email alerts on the company’s website.

Kiora Pharmaceuticals, Inc.

Nasdaq:KPRX

KPRX Rankings

KPRX Stock Data

13.13M
2.97M
0.9%
49.25%
1.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ENCINITAS